Showing results (61-70 of 123) with videos related to
Sort By:
Pageof 13
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 6, 2013
Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patientsKatrin S Reiners, Jörg Kessler, Maike Sauer, et al.Leukemia & Lymphoma|February 14, 2013
Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphomaStephanie Sasse, Achim Rothe, Helen Goergen, et al.Annals of the Rheumatic Diseases|October 21, 2011
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGEPaul P Tak, William Rigby, Andrea Rubbert-Roth, et al.Rheumatology and Therapy|April 29, 2024
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical TrialsGerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, et al.Rheumatology and Therapy|November 20, 2023
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial SpondyloarthritisAndrea Rubbert-Roth, Adriana M Kakehasi, Tsutomu Takeuchi, et al.Journal of Clinical Medicine|September 29, 2019
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau CohortsRuediger B Mueller, Caroline Hasler, Florian Popp, et al.Blood|July 13, 2012
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experienceAchim Rothe, Stephanie Sasse, Helen Goergen, et al.Molecular Cytogenetics|July 30, 2014
Molecular characterization of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patientTereza Jancuskova, Radek Plachy, Lucie Zemankova, et al.The Journal of Rheumatology|March 5, 2013
Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposureMark C Genovese, Andrea Rubbert-Roth, Josef S Smolen, et al.Rheumatology and Therapy|January 20, 2023
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical StudiesPeter C Taylor, Yun-Fei Chen, Janet Pope, et al.Pageof 13